Heron Therapeutics | HRTX - Operating Expenses


Heron Therapeutics reported $40.55M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
ALKERMES USD 1.86B 56.17M Sep/2026
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
Amarin USD 51.48M 113K Dec/2025
ANI Pharmaceuticals USD 637.11M 39.9M Sep/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 245.35M 30.35M Jun/2026
Eisai JPY 209.6B 6.14B Jun/2026
Emergent BioSolutions USD 555.9M 242.7M Jun/2023
GlaxoSmithKline GBP 6.03B 227M Sep/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Insmed USD 606.26M 79.46M Sep/2026
Ligand Pharmaceuticals USD 94.5M 39.4M Sep/2026
Merck USD 10.75B 5.02B Sep/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Neurocrine Biosciences USD 779.7M 40.6M Sep/2026
Omeros USD 59.16M 20.13M Jun/2024
Pacira USD 1.18B 995.96M Sep/2026
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Ultragenyx Pharmaceutical USD 283M 6M Sep/2026
Veracyte USD 133.73M 7.37M Sep/2026
Vertex Pharmaceuticals USD 2.18B 118.2M Sep/2026